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1. Introduction 
Malignant gliomas are the most prevalent type of primary brain tumors in adults. The most 
aggressive form, glioblastoma multiforme (GBM, WHO grade IV glioma), is characterized as 
incurable with average survivals less than 18 months (Buckner, 2003; Curran et al., 1993; De 
Angelis, 2001). Standard therapy consists of surgical resection to the extent that is safely 
feasible, followed by radiotherapy and adjuvant chemotherapy. A meta-analysis based on 
12 randomized trials has supported the use of adjuvant chemotherapy treatment as 
compared to radiotherapy alone. A five percent increase in survival at two years, from 15 
percent to 20 percent was reported (Stewart, 2002). In this context, an oral alkylating agent, 
temozolomide, has demonstrated antitumor activity as a single agent in the treatment of 
glioblastoma patients (Newlands et al., 1997; Stupp et al., 2001, 2005; Yung et al., 2000). At a 
median follow-up of 28 months, temozolomide treatment prolonged the median survival 
from 12.1 months with radiotherapy alone to 14.6 months when administered with 
concomitant radiotherapy (Stupp et al., 2005). Adjuvant administration of carmustine, a 
nitrosourea drug, has not resulted in beneficial prolongation of survival, although some 
long-term survivors in the chemotherapy groups have been documented in some of the non-
randomized phase III trials (Chang et al., 1983; Green et al., 1983). Despite these advances in 
combined radio- chemotherapy treatment strategies along with surgical resection, the 
prognosis of patients with malignant glioma is poor and ≥ 80% of the patients survive less 
than 2 years. Salvage treatments upon recurrence are palliative at best and rarely provide a 
significant survival benefit. The minor clinical benefit of radio-chemotherapy is supposed to 
be mainly based on tumour stem cells, which in analogy to normal stem cells are resistant to 
radio- and chemotherapy (Liu et al., 2006; Singh et al., 2003). Therefore, the development of 
new treatment modalities is extremely important.  
It is known that defects in the immune system play a crucial role in the development of 
cancer as well as in the host defense against cancer. Thus, specific immune therapeutic 
therapy approaches have been tested for a long time. Tumor-associated antigens recognized 
by tumor-reactive cytotoxic T lymphocytes (CTL) have been identified during the last two 
decades (Janeway et al., 2004). Also in patients with GBM such tumor antigen specific CD8+ 
T cells have been identified in the circulating blood (Tang et al., 2005). A specific cancer 
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immunotherapy can be based on the use of antibodies directed against specific antigens, 
which are expressed in tumors. However, the more recently described immunological 
therapy strategy for GBM with an antibody (Bevacizumab), which blocks angiogenesis by 
binding to the vascular endothelial growth factor also shows insufficient results (Lai et al., 
2010). The more promising strategy seems to be the use of tumor specific vaccines, which 
induce a specific cellular immune reaction by induction of tumor specific CTL.  
2. Dendritic cells in cancer therapy 
A specific cellular immune response against tumors is based on the uptake and presentation 
of tumor antigens on MHC molecules by professional antigen presenting cells leading to the 
induction of antigen specific CTL, which can then  attack the tumor. Dendritic cells (DC) are 
the most potent antigen presenting cells and have been shown to be able to induce an 
efficient and specific immune response (Banchereau & Steinman, 1998; Steinman, 1991; 
Whiteside & Odoux, 2004). In comparison to other antigen presenting cells, like B cells, 
which induce and activate only memory T cells, dendritic cells can stimulate naive T cells 
(Banchereau & Steinman, 1998; Steinman, 1991; Whiteside & Odoux, 2004). Thus, today one 
of the most promising immunological therapy approaches in treatment of various types of 
human cancer is a specific immunotherapy with autologous dendritic cells (Engleman, 2003; 
Gilboa, 2007; Nestle, 2000).  
According to their phenotype and functional properties dendritic cells can be classified as 
immature and mature type (Banchereau & Steinman, 1998). Immature dendritic cells are 
able to capture and internalize particles and soluble antigens from the environment 
(Banchereau & Steinman, 1998). Upon being internalized, antigens are processed and split 
into peptides, which are then presented on the cell surface in association with MHC 
molecules (Banchereau & Steinman, 1998). In response to micro-environmental signals 
immature DC switch to a mature phenotype with T cell stimulatory capacity (Vieira et al., 
2000; Whiteside & Odoux, 2004). Mature dendritic cells express higher levels of major 
histocompatibility complex class I and class II molecules as well as co-stimulatory molecules 
like CD80 and CD86 (Dietz et al., 2000; Whiteside & Odoux, 2004). During the maturation 
process DC lose their ability to take up and process antigens (Dietz et al., 2000; Whiteside & 
Odoux, 2004). Mature dendritic cells are characterised by a distinct cytokine expression 
profile and their increased ability to produce Interleukin 12 (IL-12) in response to 
environmental signals, a cytokine known to be necessary for induction of TH1-T cell 
response leading to production and proliferation of CTL (Whiteside & Odoux, 2004, Rouard 
et al., 2002). 
Until now several methods have been published to generate dendritic cells in vitro from 
monocytes isolated from the peripheral blood of volunteers or cancer patients, called 
monocytes-derived dendritic cells (MoDC) in the presence of GM-CSF and IL-4 (Morse et al., 
2002; Peters et al., 1996; Romani et al., 1996, Sallusto & Lanzavecchia 1994, Zhou & Tedder, 
1996). Immature MoDC can be loaded either with tumor-cell-lysate, known tumor specific 
peptides or with specific RNA or DNA. Upon exposure to various maturation stimuli the 
antigen loaded immature MoDC can be matured and are able to induce a clinical antitumor 
response in patients with various types of tumors through induction of tumor specific CTL, 
which can then  attack the tumor (Engleman, 2003;  Gilboa, 2007; Morse et al., 2002; Nestle, 
2000; Romani et al., 1996, Zhou & Tedder, 1996).   
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2.1 Dendritic cell based immunotherapy in patients with GBM  
Although the tumor is hidden behind the blood brain barrier immune cells can be recruited 
into the central nervous system (Tambuyzer et al., 2009; Vauleon et al., 2010; Wilson, et al., 
2010). Macrophages and dendritic cells are found in perivacscular zones, the choid plexus 
and the meninges (Vauleon et al., 2010). In gliomas infiltration of CD8+ as well as CD4+ T 
cells have been reported (Barcia et al., 2009; Mittelbronn et al, 2007). Thus, several types of 
immune reactions take place in primary brain tumors. In this context Ueda and coworkers 
have found T cells directed against two glioma antigens (IL13Ra2 and EphA2) within the 
peripheral blood mononuclear cells from a long surviving patient with an anaplastic 
astrocytoma (Ueda et al., 2007), showing that an efficient immune reaction in brain tumors is 
generally possible. Hoverer, the tumor itself shows variety of so-called “tumor escape 
mechanisms” which are able to dampen tumor antigen-specific immune responses. These 
include an immunosuppressive environment by secretion of immunosuppressive cytokines 
and factors such as transforming growth factor beta (TGFǃ) (Schneider et al., 2006) and 
vascular endothelial growth factor (Naumov et al., 2006), which increase the number of 
tumor infiltrating regulatory T cells and lower the number of cytotoxic killer cells and 
others. Moreover, the high expression of HLA-4 on gliomas, upon binding to NKG2A7B has 
a negative effect on T and NK cell activity (Wischhusen et al., 2005). Thus, in GBM the 
immune reactions are mostly not effective as shown by the unfavorable course of the disease 
and the high level of recurrences. A specific immunotherapy based on ex vivo generated 
antigen loaded monocyte-derived dendritic cells may overcome this inhibition leading to a 
re-induction of an efficient immune reaction against GBM. Such immune responses require 
antigen recognition. Several groups demonstrated an over-expression of several antigens 
including a mutated form of the Epidermal Growth Factor Receptor (EGFRvIII), GP 100 and 
MAGE 1 (Okada et al., 2009; Saikali et al., 2007), which could be used as targets for 
induction of an antigen specific immune response by priming the MoDC with peptides from 
these antigens.  However, using the whole tumor cell lysate as well as tumor RNA as 
antigen source may probably reduce the risk of an immune evasion due to clonal expansion 
of antigen-loss tumor cell variants (Jäger et al, 1996, Vauleon et al., 2010).  
Several reports have demonstrated that specific cellular immunotherapy using dendritic 
cells is capable of inducing a clinical antitumor response within the immunologically 
privileged brain, confirming that the central nervous system (CNS) is accessible to this kind 
of immunotherapy. Table I gives an overview on clinical studies with dendritic cell vaccines 
performed for glioma patients. The published data are based on phase I and II trials as well 
as on case reports including in total over 200 patients with GBM and over 100 patients with 
anaplastic astrocytomas or other malignant brain tumors (table 1). Two studies and one case 
report include children or young adults (Ardon et al., 2010a; Caruso et al., 2004; De 
Vleeschouwer et al., 2004). The dendritic cells used in these studies were ex-vivo generated 
from patients blood monocytes using the described standard procedure and primed with 
peptides, autologous tumor cell lysates or tumor-derived RNA. In two trials dendritic cells 
were fused with autologous tumor cells (Kikuchi et al., 2001, 2004). Dendritic cells were 
further matured by exposure to various maturation stimuli (Ardon et al., 2010a, 2010b; De 
Vleeschouwer et al.; 2008; Kikuchi et al., 2004; Okada et al., 2007; Rutkowski et al., 2004; 
Yamanaka et al., 2005) or were used without further maturation signals (Caruso et al., 2004; 
De Vleeschouwer et al., 2004; Kikuchi et al., 2001; Liau et al., 2000, 2005; Yamanaka et al., 
2003; Yu et al., 2001, 2004).  
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Antigen source type of trial responses author 
tumor cell lysate + 
TLR-7 ligand  
(children) 
Phase I
 
median OS:  
12.2 months 
Ardon et al., 2010a 
tumor cell lysate Phase I/II median OS:  
24 months 
Ardon et al., 2010b 
tumor RNA 
(children, young  
adults) 
Phase I
(relapsed brain 
 tumors) 
1 PR, 4 SD Caruso et al., 2004 
tumor cell lysate 
(4-year old child) 
case report 
(recurrent GBM) 
CR over 2 years De Vleeschouver et al. 2004 
tumorc ell lysate Phase I/II
(recurrent GBM)
median OS: 
9.6 months
De Vleeschouver et al. 2008 
tumor cell lysate case report
(recurrent GBM)
median OS:
11 months
Khan & Yaquin, 2006 
fusion with tumor cells  Phase I 1 MR, 4 SD, 2 SD Kikuchi et al., 2001 
fusion with tumor cells  Phase I
(recurrent GBM)
1 SD in GBM Kikuchi et al., 2004 
peptides case report
(recurrent GBM)
no survival benefit Liau et al., 2000 
tumor cell lysate Phase I
de novo vs. 
recurrent GBM
median OS: 
23.4 months vs. 
18.3 months
Liau et al., 2005 
tumor cell lysate or 
irradiated tumor cells 
Phase I 2 PR
irradiated  tumor 
cells
Okada et al., 2007 
tumor cell lysate  Phase I 
(recurrent GBM)
median OS :
10,5 months 
Rutkowski et al., 2004 
EGFRvIII antigen Phase I median OS: 
22.8 months
Sampson et al., 2009 
inactivated tumor 
cells 
Phase I 12-/18-months 
survival: 46%/23% 
Walker et al., 2008 
tumor cell lysate  Phase I/II 
vaccine + chemo  
vs. vaccine alone
2-year-survival 
42% vs. 8%  
Wheeler et al., 2004 
tumor cell lysate Phase II
(de novo vs.  
recurrent GBM)
median OS: 
642 vs. 430 days 
Wheeler et al., 2008 
tumor cell lysate Phase I/II OS: > 200 weeks Yamanaka et al., 2003 
tumor cell lysate  
+ TLR-4 ligand 
Phase I/II
(recurrent GBM) 
median OS: 480 
(+ TLR-4 ligand)  
vs. 400 days 
Yamanaka et al., 2005 
antigens  Phase I median OS: 
455 days 
Yu et al., 2001 
Abbreviations: OS: Overall Survival; PR: Partial Remission; CR: Complete Remission;  
SD: Stable Disease 
Table 1. Clinical Studies for GBM treated with autologous DC 
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For all used methods of MoDC generation a clinical response was described. With the 
exception of one trial (Yamanaka et al., 2003), where some patients receive an intracerebral 
injection of dendritic cells, the vaccines were administered intradermally or subcutaneously. 
The reported side effects were in general low besides one case with grade IV neurotoxicity 
(Yamanaka et al., 2005). Such reactions are probably based on an excessive inflammatory 
process within the brain leading to the development of severe edema. Based on our 
experiences, in those cases, an immune suppressive treatment with corticosteroids has to be 
accompanied to modulate the highly inflammatory process, which can of course counteract 
the efficacy of the immune response. The reported major side effects are short term flu like 
symptoms like fever, headaches and chill. Thus, this treatment is well tolerable without 
having a negative impact on the quality of life.   
Clinical responses based on radiological findings, which were performed for a part of the 
treated patients (n=108 patients with GBM) consisted of complete remissions (3.7 %), partial 
remissions (4.6 %), stable diseases (12.9 %) and mixed responses (5.5 %). In some trials a 
prolongation of the overall survival compared with historical data or non randomized 
control groups are described (Ardon et al., 2010b; De Vleeschouwer et al.,  2008; Liau et al., 
2005; Sampson et al., 2009; Rutkowski et al., 2004; Wheeler et al., 2008; Yamanaka et al., 2003, 
2005; Yu et al., 2001, 2004). In a pilot trial published by Ardon and coworkers 8 patients with 
de novo diagnosed GBM received an immunotherapy with tumor cell lysate pulsed 
dendritic cells after surgery and radio-chemotherapy. The median overall survival was 24 
months ranging from 13 to 44 months (Ardon et al., 2010b). Comparable results with a 
median survival of 22.8 months are reported from Sampson and coworkers using dendritic 
cells pulsed with the mutated EGFRvIII antigen coupled to KLH (Sampson et al., 2009). 
Even in patients with relapsed GBM a dendritic cell therapy is reported to be successful. De 
Vleeschouwer and coworkers reported a case of a 4 year old child, who received a dendritic 
cell therapy after surgery of recurrence. 2 years after onset of the immune therapy the child 
still remains in a complete remission (De Vleeschouwer et al., 2004). In a phase I/II trial 
performed by the same group (De Vleeschouwer et al., 2008) 56 patients were treated with 
dendritic cells pulsed with tumor cell lysate after surgery of recurrences. The median overall 
survival was 9.6 months with a 2-year survival rate of 14.8 % after onset of the therapy.  
Besides these very promising results the objective clinical responses are low and a lot of 
patients fail to respond to the therapy. One main reason for low clinical efficacy of MoDC-
based anticancer therapies could be due to low IL-12 and high IL-10 production by the 
MoDC favoring a TH2 rather than a TH1 immune response. In fact, a lot of clinically 
approved maturation protocols mature MoDC insufficiently in a TH1-polarizing direction 
(Hildenbrandt et al., 2007, 2008; Mailliard et al., 2004; Zobywalski et al., 2007). Hildenbrandt 
and coworkers found that the used cytokine cocktail with TNF-a, IL-1ß, IL-6 and PGE2 
according to Jonuleit et al. (Jonuleit et al., 1997) induce the phenotypic characteristics of fully 
matured MoDC expressing high levels of CD83, MHC, costimulatory molecules and CCR7, 
but secrete high levels of IL-10 and only low levels of IL-12p70 suggesting a preference for a 
TH2-polarisation (Hildenbrandt et al., 2008). For this reason, improved maturation protocols 
are required. In this context the activation of Toll-like receptors (TLR) by adding TLR-
ligands to the MoDC cultures becomes an interesting alternative to mature monocytes-
derived dendritic cells.  
2.1.1 Toll-like receptor agonists in maturation protocols for dendritic cells 
The expression of certain Toll-like receptors (TLR), a family yet 11 identified transmembrane 
receptors, expressed on dendritic cells plays a crucial role in the recognition of microbial or 
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viral infections (Medzhitov, 2001). TLR mediated activation of dendritic cells is supposed to 
be vital for the generation of a TH1 effector response (Schnare et al., 2001). Thus, TLR 
ligands, which are molecular signatures of microbial or viral infections, may signal the 
presence of an infection (danger signal), which leads to maturation of DC with a TH1 
polarization profile (Akira et al., 2001; Medzhitov, 2001). Interestingly, the TLR 3, a cell 
surface receptor for double-stranded RNA as well as for the synthetic analogue poly I:C, is 
predominantly expressed on dendritic cells (Alexopoulou et al., 2001; Muzio et al., 2000). 
Bone marrow derived immature dendritic cells activated by poly I:C produce large amounts 
of IL-12 and up-regulate MHC as well as co-stimulatory molecules on their surface 
(Alexopoulou et al., 2001).  
Several TLR are also expressed on monocytes and immature monocytes-derived dendritic 
cells (Visintin et al., 2001). Moreover, it has been shown that immature MoDC have an 
increase in TLR 3 expression as compared to monocytes, indicating that in MoDC this TLR 
may play an important role (Visintin et al., 2001). At the ASCO meeting 2007 our group have 
show that immature MoDC from patients with GBM when activated by adding the TLR 3 
ligand poly I:C switch to a mature phenotype with up-regulation of the maturation marker 
CD83 and of co-stimulatory molecules. After short time exposure to IFN-┛ these matured 
MoDC were able to produce IL-12p70 at a higher level than IL-10 which clearly favours a 
TH1 response (Nesselhut et al., 2007). Moreover the IL-12/IL-10 ratio seems to be correlated 
to clinical response. The use of poly I:C is currently tested in a phase I/II trial and recent 
published data show that poly I:C boosted DC are safe and have clinical anti tumor activity 
(Okada et al., 2010). Furthermore, the authors found a correlation between the IL-12 
production level and the time to progression (Okada et al, 2010). Comparable data was seen 
by Yamanaka and coworkers using DC matured with a ligand to TLR 4. Patients who 
received TLR matured DC had longer survival than those vaccinated with immature DC 
(Yamanaka et al., 2005). Van Gool et al. reported an improvement of the progression free 
survival of glioma patients, when the skin at the injection site of the mature DC was 
pretreated with the TLR-7 agonist Imiquimod (van Gool et al., 2009). Concordant with 
findings from our group Hildebrandt et al. found that the addition of INF-γ to TLR-agonists 
can improve the maturation status as well as the TH1 polarization of MoDC (Hildenbrandt 
et al., 2008). However, most TLR-agonists are not clinically approved and therefore are not 
allowed to be used in clinical trials, yet. In this context it is interesting, that Hildenbrandt et 
al. could show that IFN-γ when added to the clinical-grade cytokine cocktail (Jonuleit et al., 
1997) induces the production of lower levels of IL-10 and higher levels of IL-12p70, 
demonstrating the TH1-prolarizing capacity of this cytokine (Hildenbrandt et al., 2008).  
2.1.2 Impact of cancer induced immune suppression on the efficacy of denditic cell 
therapy  
During the last years several investigations show an increasing evidence of a strong 
association between chronic infection, inflammation and cancer development as well as 
tumor progression (Balkwill & Mantovani, 2001; Coussens & Werb, 2002). Inflammation is a 
physiological process occurring after tissue damage, infections caused by microbial or viral 
pathogen, chemical irritation or wounding (Philipp et al., 2004.) In fact, many of the same 
inflammatory mediators that are secreted by wounds are found in the tumor 
microenvironment. Immune cells infiltrate into the developing tumor site and establish an 
inflammatory tumor microenvironment (Balkwill & Mantovani, 2001; Whiteside, 2008). As 
wound healing is self limited cancer can be described as “wounds that do not heal” (Dvorak, 
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1986). Meanwhile it is well established that the tumor per se can change the immunological 
balance into an inflammatory microenvironment by release of certain cytokines and 
chemokines leading not only to the promotion of tumor growth but also to the inhibition of 
an efficient immune response. This may be one of the reasons for an unsuccessful 
immunotherapy for GBM patients based on dendritic cells (Couldwell et al., 1991, Nitta et 
al., 1994, Hishii et al, 1995, Weller & Fontana, 1995). An example is the intratumoral 
expression of TGF-ß, which can suppress an adaptive antigen specific immune response. 
Moreover, TGF- ß expression was shown to be a predictive factor for the clinical outcome in 
vaccinated patients (Liau et al., 2005).  
Taken together, an efficient induction of a clinical antitumor response requires both a 
polarization of MoDC in a TH1 direction as well as a change of the immune suppressive 
tumor associated microenvironment. Beside several cytokines which promote an immune 
suppressive microenvironment, regulatory T cells (T-reg), which are required for 
maintaining immunological self tolerance (Sakaguchi, 2005), play an important role in the 
regulation of an immune response and thus may limit an antigen specific immune response 
in cancer (Borsellino et al. 2007; Deaglio et al. 2007; Mandapathil et a., 2009; Nizar et al, 
2009).  
Several subpopulations of T-reg have been described (Sakaguchi, 2005; Seddiki et al., 2006). 
Most commonly used is the CD4+, CD25 +high, CD127-/dim phenotype with intracellular 
expression of the transcription factor FoxP3 (Seddiki et al., 2006). More recently, a sub-
population of CD39+ T-reg was described (Borsellino et al. 2007; Deaglio et al., 2007). CD39 
belongs to the family of ecto-nucleoside triphosphate-diphosphatehydrolase-1 and 
hydrolyses extracellular ATP. This leads to a pericellular accumulation of the nucleoside 
adenosine, which is known to play an important role in inhibiting effector functions of 
activated T cells (Borsellino et al. 2007, Huang et al., 1997). The authors propose that the 
immune suppressive activity of T-reg is partly due to this enzymatic activity of CD39 and 
thus may play a crucial role in inhibition of antigen specific T cell response. Woo et al. were 
the first who reported an increased percentage of T-reg cells in tumor infiltrating 
lymphocytes in non-small-cell-lung cancer and ovarian cancer (Woo et al., 2001). Meanwhile 
accumulating T-reg cells are detected in the tumor microenvironment, ascites as well as in 
the peripheral blood of cancer patients and have been associated with poor prognosis (Beyer 
& Schultze 2010; Nizar et al. 2009, Wolf et al., 2003).  
Our group have shown that  subpopulations of T-reg  characterized by a CD4+, CD25 +high 
as well as CD127-/dim or CD39+ expression profile can be detected in the peripheral blood 
of healthy donors, tumor free patients as well as patient with tumor load (Neßelhut et al., 
2009). The percentage of T-reg was significantly higher in cancer patients, including patients 
with GBM, as compared to healthy donors. Moreover, patients with advanced tumors show 
higher levels of T-reg cells as compared to patients with no evidence of disease. Several 
other groups reported an increase of T-reg cells in GBM patients in peripheral blood as well 
as within the tumor microenvironment (Fecci et al., 2006a; Grauer et al., 2007; Hussain et al., 
2006, El Andaloussi et al., 2006).  Measurement of T-reg cells along with an immune therapy 
may be useful to discriminate between non- responding and responding patients. In fact, 
first analysis of our group show that rising T-reg numbers are partly associated with lack of 
clinical response to a dendritic cell therapy in patients with GBM. Thus, the elimination of 
excessive T-reg cell numbers seems to be a promising approach to improve the efficacy of a 
dendritic cell based immune therapy.  
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Several chemotherapeutical agents have immune stimulatory and T-reg modulating effects 
when used at lower dosages with reduced toxic effects (Nizar et al., 2009). Beside this option 
there are some reagents which target T-reg directly through recognition of CD25 (Morse et 
al., 2008, Fecci 2006 b) or through CTLA-4 blockade (Ribas et al., 2009). Some of these 
approaches are tested in association with DC therapy in cancer (Chiringelli et al, 2004, Ribas 
et al. 2009, Morse et al., 2008) including GBM (Fecci ate al. 2006 b, Maes et al., 2009). 
Interestingly, in a rat glioma model low dose temozolamide could also decrease the number 
of T-reg cells. (Banissi et al, 2009). In this context it is noteworthy that Wheeler et al. show 
that GBM patients, who responded to DC therapy, also exhibited a better response to a 
following chemotherapy (Wheeler et al., 2004). In the study published by Ardon et al. 
immunotherapy based on dendritic cells started after radio-chemotherapy (Ardon et al., 
2010b). One can suppose that the chemotherapy with temozolamide has lead to a decrease 
of T-reg cells and thus enhanced the immunological response causing the high 24 months 
median survival for the treated patients. The combination of dendritic cell therapy and 
adjuvant chemotherapy was also tested in malignant astrocytomas (Walker et al., 2008). The 
12- and 18-months survival rates were 46% and 23%, respectively. Depletion or inhibition of 
T-reg may thus improve the efficacy of dendritic cell based therapy. 
2.1.3 Newcastle disease virus in treatment of GBM; a tool for improving DC therapy 
Besides dendritic cell therapy another promising approach for the treatment of malignant 
brain tumors is the treatment with replication-selective viruses, also called oncolytic viruses. 
This is based on the fact that most tumor cells are more or less unable of an effective virus 
defense. This approach is also known as virotherapy. The application of viruses for cancer 
treatment is based on reports since the beginning of the 20th century on temporary 
improvement of cancer following natural viral infections or vaccinations against viral 
diseases. (DePace 1912). Meanwhile several replication competent viruses (mainly herpes 
and adenoviruses) were tested in vitro, in animal models as well as in phase I/II clinical 
trials for treatment of malignant brain tumors (Shah et al., 2003; Rainov & Ren, 2003; 
Wollmann et al., 2005). However, the viruses have to be genetically modified in a way that 
makes sure that they selectively infect and replicate in tumor cells. Within the viruses tested 
for human anticancer treatment the Newcastle Disease Virus (NDV), an enveloped poultry 
virus with single strained RNA as genetic material, seems to be one of the most promising 
candidates. NDV is not a pathogen for humans, and is absolutely harmless causing only 
mild flu-like symptoms or conjunctivitis in the worst of cases (Lorence et al., 2001; Reichard 
et al., 1992). NDV shows a natural distinct tropism for cancer cells. Cancer cells infected with 
NDV can be killed directly by the virus within a short time after infection, whereas normal 
infected cells are not lysed by NDV. 
As described earlier tumor cell lysate may be the better antigen source for priming of 
dendritc cells because it contains the whole antigen repertoire of the tumor. However, it has 
to be taken in mind that most of the antigens expressed in tumors are poor inducers of 
immune response and are often recognized by the immune system as self antigens (Vergati 
et al., 2010).  Opposed to this adjuvant active specific immunization based on tumor cells 
modified with a low pathogenic strain of the NDV has been reported to achieve sustained 
immune responses in patients with advanced colonic cancer and liver metastasis (Lehner et 
al., 1990 Schulze et al., 2009). NDV can have lytic activity on tumor cells directly as well as 
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immune stimulating properties that affect both innate and adaptive immune responses. 
Infection of tumor cells with live NDV results in a potent up-regulation of cell adhesion 
molecules on the tumor cells surface (Lehner et al. 190; Wasburn et al., 2002). Moreover, 
NDV infection of tumor cells leads to an improved tumor cell / T cell interaction and an 
increased T cell co-stimulatory activity (Ertel et al., 1993; Termeer et al., 2000). Expression of 
viral proteins on the tumor cell surface and presence of virus derived pathogen-associated 
molecular patterns (e.g. double-stranded RNA) result in breaking of host tolerance towards 
the tumor in vitro (Bai et al., 2002). The T cell stimulatory action of dendritic cells pulsed 
with lysates of NDV infected tumor cells as well as the antitumor cytotoxicity of 
macrophages and monocytes is increased (Schirrmacher et al., 2000; Washburn et al., 2003; 
Zeng et al., 2002). Finally, NDV induces an increased production of various cytokines, e.g. 
Interferon-ǂ as well as chemokines, influencing the migration, the activation status and 
cytotoxic activity of various immune cells (Lokuta et al., 1996; Schirrmacher 2005, Schlag et 
al., 1992). Clinical phase I and II studies in various tumor entities have proven the safety of 
active specific immunization with NDV-modified tumor cells. A detailed description of the 
mechanisms of action of NDV modified tumor cell vaccines and results from other studies in 
cancer patients were reviewed by Schirrmacher (Schirrmacher, 2005).  
In malignant brain tumors case reports as well as clinical phase I/II studies have shown that 
treatment with intravenously applied NDV as well as with vaccines utilizing NDV modified 
tumor cells can induce a clinical anti-tumor response in malignant brain tumors with 
objective clinical responses as well as with a trend towards improvement of overall survival 
(Csatary & Bakacs, 1999, Csatary et al., 2004; Freeman et al., 2005; Schneider et al., 2001; 
Wagner et al., 2006). Recent results from our group show that a therapy with dendritic cells 
in combination with the NDV virotherapy may improve the clinical anti-tumor response in 
patients with GBM (Neßelhut et al., 2007, 2011). Patients were pre-treated with 
intravenously administration of NDV. Dendritic cells were primed with NDV modified 
tumor cells or with NDV alone in patient with tumor recurrence. When tested in vitro, NDV 
primed MoDC of such treated patients induce the activation of autologous CD8+ T cells 
with release of IFN-┛. This leads to the hypothesis that, if viral antigens are expressed on the 
tumor cell surface, a NDV specific dendritic cell based therapy may lead to the induction of 
NDV specific CD8+ T cells and thus to the induction of a specific immune response against 
the virus infected cancer cell (Neßelhut et al., 2011). 
3. Conclusion 
Taken together a dendritic cell therapy as well as the NDV virotherapy have shown clinical 
efficacy and have been proven to be safe with only minimal side-effects. Especially patients 
with primary resistance against temozolamide caused by the MGMT status could benefit 
from such alternative therapy strategies. Furthermore, new insights in the nature and 
biology of glioma tumor stem cells may improve an immunological concept by using tumor 
stem cell specific antigens as targets in dendritic cell therapy as it was recently shown 
(Pellegatta et al., 2006,  Stupp & Hegi, , Xu et al., 2009). An immunotherapy with dendritic 
cells can either be used in adjuvant, curative settings to avoid or delay tumor recurrence or 
in palliative settings to keep the disease stable offering the patients a chance for prolonged 
overall survival. Based on current results it has to be supposed that patients with minor 
tumor burden or no evidence of disease are the best candidates for an immunotherapy.  
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The main reasons for a deficient anti-tumor immune response are most likely the immune 
suppressive tumor microenvironment and the up-regulation of immune suppressive cells. 
Thus, a combination with therapies, which can modulate the tumor microenvironment as 
well as lower the percentage of the immune suppressive T-reg cells should be considered as 
treatment prior to or in combination with dendritic cell based immune therapy. 
Additionally, glioma cells are considered to be poor antigen-presenting cells. In order to 
promote antigen-specific recognition and avidity of potential anti-tumor effector cells, the 
biology of antigens expressed by malignant glioma cells must be taken into consideration 
while designing protocols for programming autologous dendritic cells and defining the 
appropriate patient. For example, Prins and coworkers could recently shown that the gene 
expression profile of the individual glioma can identify a subgroup of patients, that may be 
more responsive to dendritic cell based immunotherapy (Prins et al., 2011). In this context 
the combination with NDV seems to be a promising tool to modify tumor cells in vitro as 
well as in vivo to a more immunogenic phenotype resulting in better immune recognition as 
well as in better immune response.  
The encouraging results of phase I/II trials have to be confirmed in phase III studies with 
special emphasis on the maturation protocols for improvement of TH1-polarisation of 
dendritic cells, which so far are still a matter of controversial discussion. Moreover, the 
optimal antigen source, cell number of injected dendritic cells, frequency of vaccinations as 
well as the right time point for vaccination are still not fully defined. Future studies should 
also involve an immune monitoring of vaccinated patients. Immune monitoring methods 
can include quantification of CD8+ and CD4+ T cells generated in response to the antigen or 
measurement of the functional status of T cells analyzed by cytokine production. However, 
it has to be taken into account that in vitro measurement of T cell responses do not always 
correlate with clinical outcome (Carpentier & Meng, 2006).  Thus, the best immunological 
monitoring strategy is still intensively debated.  
Finally, clinical trials for the evaluation of immune therapeutical approaches have to be 
designed in a different way as for chemotherapeutical drugs. In this context the overall 
survival rather than the reduction of tumor burden is probably the best primary endpoint. 
Based on such a study design ProvengeTM, an immunological treatment based on antigen 
presenting cells, received the FDA approval for treatment of hormone refractory prostate 
cancer in spring 2010. 
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